News - Certolizumab pegol
BRUSSELS, June 1, 2012 /PRNewswire/ -- UCB, a leading biopharmaceutical company, is sponsoring several data presentations for its immunology portfolio at the European League Against Rheumatism
Efficacy, Safety, and Improvements in Work Productivity and Daily Activities with Certolizumab Pegol (CZP) After Incomplete Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Patients with Low to Moderate Disease ActivityIn RA patients with longstanding low to moderate disease activity, the addition of CZP to non-biologic DMARDs was well tolerated and associated with increased rates of remission, prevention of disease worsening, and improved work productivity and daily activity. 2214 - Tuesday, November 8, 9:00 am - 6:00 pm, Poster Hall Baseline Tender Joint Count Scores Predict Long-Term Household Productivity in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol Plus MethotrexateAt baseline (BL) higher tender/swollen joint counts (TJC/SJC) scores were associated with increased impairment in household productivity. Improvements in household productivity were seen with CZP treatment in both patients with lower versus higher BL TJC scores, with greater improvements in patients with lowest BL TJC scores. 1245 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall Expectations of Treatment Goals and Goal-Setting Practices in People with Rheumatoid ArthritisA new survey of people living with RA shows that a targeted approach to successful disease management means setting personal, social, and treatment goals and monitoring progress to achieve these goals. The survey also found that respondents wanted guidance from their HCPs in determining and setting these goals to assess for themselves whether their treatment is working. As more treatment options become available for RA, it is likely that the expectations of people with RA will increase as well. 106 - Sunday, November 6, 9:00 am - 6:00 pm, Poster Hall RAPID3 Data